Evidence map›Paper›PMID 42703264›Full record

ArticleTherapeutic advances in rare disease

Progress and perspectives in primary mitochondrial myopathy: Highlights from the 2025 mitochondrial medicine masterclass with a focus on TK2 deficiency.

Austin Larson, Jared Goettemoeller, Ken Goettemoeller, Linda Goettemoeller, Amy Goldstein, Nikki Huggan, Amel Karaa, Megan Leahey, Fernando Scaglia, Philip Yeske and 2 more

Abstract read
In one paragraph

Article in Therapeutic advances in rare disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Austin LarsonPediatrics-Clinical Genetics and Metabolism Department, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Jared GoettemoellerUnited Mitochondrial Disease Foundation, Pittsburgh, PA, USA.
Ken GoettemoellerUnited Mitochondrial Disease Foundation, Pittsburgh, PA, USA.
Linda GoettemoellerUnited Mitochondrial Disease Foundation, Pittsburgh, PA, USA.
Amy GoldsteinMitochondrial Medicine Frontier Program, Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nikki HugganUnited Mitochondrial Disease Foundation, Pittsburgh, PA, USA.
Amel KaraaMassachusetts General Hospital, Genetics Division, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0001-5781-9824
Megan LeaheyUnited Mitochondrial Disease Foundation, Pittsburgh, PA, USA.
Fernando ScagliaBaylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
Philip YeskeUnited Mitochondrial Disease Foundation, Pittsburgh, PA, USA.
Zarazuela Zolkipli-CunninghamMitochondrial Medicine Frontier Program, Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0002-0743-8879
Michio HiranoNeuromuscular Medicine Division, Columbia University Irving Medical Center, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inaugural United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine 2025 Masterclass focused on primary mitochondrial diseases (PMDs) especially primary mitochondrial myopathies (PMMs) and thymidine kinase 2 deficiency (TK2d). The Masterclass featured leading US experts in the field, providing the latest scientific and clinical knowledge, as well as patients and caregivers sharing their lived experience of mitochondrial diseases. In this report, we summarize the key highlights of each presentation. An overview of PMM featuring the etiologies of different PMMs and key features of notable PMMs, was followed by a presentation discussing the practical clinical processes of diagnosing PMM, how the roles of clinicians have evolved as diagnostic technology has improved, and actions clinicians can take to maximize the chances of an early, accurate diagnosis. Real-world case studies highlighted variations in disease presentation among the wide range of PMMs, which was followed by an in-depth review of clinical assessments and symptom management for PMM across organ systems. Multisystemic disorders like PMM require multidisciplinary management, in both a chronic and acute setting, and two experts discussed the practical workflow for clinicians to build a multidisciplinary model of care at their hospitals, the roles and responsibilities of the lead coordinator and each subspecialist, and practical steps that clinicians can take to manage acute care coordination and decrease acute care utilization. A hypothetical case study of TK2d (based on real patients) brought together the different aspects of PMM discussed during the Masterclass, while the patient perspective presentations allowed patients and caregivers to discuss the real-world impact that the diagnostic and care journey had on them and their families. This Educational Masterclass provided detailed knowledge of PMM designed to provide the next generation of clinicians and investigators with practical, actionable guidance and resources they could utilize to make a difference in the lives of patients with PMM.

Indexed as

mitochondrial diseasemitochondrial myopathyTK2d

Identifiers

PMID42703264
PMCPMC13546419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.